The automated continuous -amylase assay using p-nitrophenyl-a-D-maltoheptaoside (Boehringer Mannheim) äs Substrate on the Hitachi 705 clinical cheniical analyzer, was compared with the Phadebas® Kinetic Amyläse Assay (Pharmacia Diagnostics) on the Hitachi 705. The two methods showed good correlation.
Introduction
Continuous amyläse assays have recently been introduced by several manufacturers. Unfortunately the various methods are difficult to compare with each other because of differences in the Substrates used. At least four different Substrates are in common use: p-nitrophenyl-a-D-maltoheptaoside (Boehringer Mannheim), maltotetraose (General Diagnostics), a J. Clin. Chem. Clin. Biochem. / Vol. 22,1984 / No. l mixture of oligosaccharides containing a known amount of polymers with 4 to 10 glucose residues (Merz-Dade) and a carboxymethylated starch (Pharmacia Diagnostics). Differences in the specificity of amyläse to these Substrates make various standardization procedures necessary. So far no recommended standardization procedure is available for amyläse.
The assay for amylase isoenzymes has been used to separate the various amylase isoenzymes, which mainly originale in the pancreas and salivary glands. Electrophoretic (1-3), electrofocusing and Chromatographie (4) techniques, and Inhibition tests (3, 5, 6) have been used in this assay. The inhibitor protein from wheat (Triticum aestivum) exhibits 100-fold specifity for human salivary (S) s compared to human pancreatic (P) amylase (5), which makes it suitable for inhibitor assay of amylase isoenzymes. A RIA method has also been introduced for salivary isoamylase (7) .
The aim of this study was to evaluate the application of two continuous amylase tests and of an automated isoamylase assay on the Hitachi 705 automatic clinical chemical analyzer. 
OL-Amylase Standards
Human-based Phadebas® IsoAmylase Test Serum Standards (P/S 0.1-8) and Humylase H, M and L control serums containing high, medium and low levels of amylase, and high and low P/S ratios were all from Pharmacia Diagnostics. Isoamylase Standards were also prepared in our laboratory from a pooled sample of saliva (total amylase activity concentration 300 kU/1) and from a sample with high pancreatic amylase (total amylase 30 kU/1) obtained from a pancreas drain. These samples were diluted in phosphate buffer, 50 mmol/1, pH 6.9 and assayed for exact amylase activity, and were mixed to yield P/S ratios 0.1-10.
Amylase Inhibitors
Amylase inhibitor from wheat seeds (Triticum aestivum) was obtained from Sigma Chemical Co., St. Louis, MO 63178, containing 2700 inhibiting units per mg of protein. Inhibitor stock solution was prepared by dissolving the contents of one inhibitor vial (5 mg protein corresponding to 13500 inhibiting units) in 1.0 ml of tris buffer, 20 mmol/1 containing NaCl 10 mmol/1, pH 8.0.
This solution was diluted 1/100 in the phosphate buffer, and in> mediately before use it was further diluted 1/4 in the same buffer.
The inhibitor Solutions were stored frozen. Additionally, inhibitor from the Phadebas® IsoAmylase Test Kit was used and the lyophilized wheat inhibitor redissolved ceordingto the manufacturer's recommendations. The inhibitor solution was diluted 1/3 in the phosphate buffer before use.
Isoamylase assay with Inhibition 150 μΐ of Standards, controls or samples werepipetted in duplicate into glass tubes. 150 ul of the phosphate buffer was pipetted into one tube of the duplicates and 150 μΐ of the inhibitor working solution into the other. The tubes were mixed and analysed for total amylase activity after at least 5 min at room temperature. The fraction remaining uninhibited was calculated. Then the stand ard curve was constructed in which the uninhibited fraction is related to the P/S ratio in the Standard. The P/S ratio in samples and controls was read frorh this curve. After correcting for the dilution (x2) in controls and samples, the P and S isoenzyme activity concentrations were calculated (5): P (Pancreatic) amylase (U/l) = Total amylase x / P/S V U + P/S/ S (Salivary) amylase (U/l) = Total amylase --P In addition the isoamylase assay with the Phadebas® Kinetic IsoAmylase method was also performed on the Hitachi 705. The inhibited and uninhibited reactions were performed automatically in the analyser, which calculated the activities directly. The Standard curve relating uninhibited fraction to the P/S ratio was constructed and the results calculated s above.
Results

Total continuous amylase assay on the Hitachi 705
The routine amylase assay in our laboratory is the Boehringer continuous method for the Hitachi 705. This was compared with the Phadebas® Kinetic Amylase Test in the same analyser.
The day-to-day and within-day coefficients of Variation of the two methods are presented in table 2. The Boehringer amylase assay is linear at least to 3500 U/l, whereas the Phadebas® kinetic method in the Hitachi 705 was not linear above 750 U/l.
An excellent correlation was found between the methods compared, s will be seen in figure 1 . The same assay level in the two methods was achieved by standardizing both with human serum. However, the results from various commercially available serums differed considerably from one method to the other. Normally there was no need for daily standardization of the Boehringer amylase method.
Isoamylase assay
The routine Boehringer continuous total amylase assay was used combined with preliminary incubation of 5 min with the inhibitor at room temperature to separate the pancreatic (P) isoenzyme from salivary (S) isoenzyme. The incubation time proved to be long enough together with about 10 min processing time of the Instrument before starting the measurement. Figure 2 shows the Standard curves for the various methods relating the uninhibited amylase fraction to the respective P/S ratio in the Standard. The inhibitor from Sigma was adopted for our routine amylase assay because of its commercial availability. In figure 3 the linearity of the assay is shown for the P and S amylase isoenzymes. The curves are constructed by analyzing total amylase and isoamylase from a serial dilution of a patient serum with high total amylase activity concentration (3500 U/l) and low P/S ratio. The assay for total amylase activity is linear at least to 3500 U/1, but the total activity must be diluted below 1000 U/l for the isoamylase assay. A patient serum containing elevated total and S amylase activity was diluted and assayed for total amylase and P and S isoamylases.
(O) total activity, (O) S activity, ( ) activity concentration.
In table 3 the coefficients of Variation are summarized for the within-day and day-to-day analyses of the P and S isoamylases. The coefficients were determined by assaying both patient serum samples containing normal or elevated total amylase, and high, normal and low P/S ratios and with Phadebas® human based Standards. The Phadebas® Standards gave somewhat higher Variation coefficients.
Tab. 3. The within-day and day-to-day coefficients of Variation in the isoamylase assays at various P/S rations at normal or slightly elevated serum amylase concentration.
A. Boehringer continuous method Human-based serum samples made in our laboratory. 13.8 6.4 Isoamylase assays from seiüm samples Total serum amylase, and P and S isoamylase activities were determined from apparently healthy normal subjects (34 of both sexes, tab. 4), ages 32.2 ± 10.3 years (rneän ± SD), ränge 16-58 years. The total amylase activities were not statistically different in the sexes. Females however had significantly (p <0.001) higher P isoamylase activity äs compared to males.
Tab. 4. Amylase and isoamylase activity concentrations in normal subjects (means ± SD).
Subjects n Mean amylase activity concentration (U/l) ± SD Total Pancreatic (P) Salivary (S) 
Discussion
Automated total amylase assays have been introduced in routine laboratories, using the continuous mode of analysis with commercially available kits (6) . One difficulty is, however, the variety of Substrates used in the assay kits pending international recommendations.
In The clinical value of serum isoamylase measurements is still a matter of controversy. The usefulness of the electrophoretic method has been criticized mainly because of the laborious methodology together with a somewhat questionable value in clinical decision-making. The present isoamylase test makes possible a fast and easy evaluation of pancreatic and salivary type isoamylase activities. Previous studies have shown that results of the inhibitor tests correlate with the electrophoretic method (3). Although a considerable bias between the methods may exist, further studies are however needed to assess whether this correlation is valid in all clinical situations. These studies are now in progress in our laboratory^and will be published later.
